SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand)

Summary

The purpose of the pilot study is to evaluate the safety and the individual efficacy of the use of ProtheraCytes® in patients with acute myocardial infarction and decreased ejection fraction. CD34+ cells will be re-injected using a dedicated catheter pushed through the femoral artery up to the left ventricle, thus avoiding open chest surgery.

Timeline

Start

2018-11-27

Primary completion

2020-06-30

Completion

2021-07-31

Outcome

Outcome not reported

Stopped: “Because of the Impact of CoviD19 pandemy”

Drugs

Indications